AbCellera to Initiate Clinical Trial of LY-CoV1404 Against Viral Variants of COVID 19

 AbCellera to Initiate Clinical Trial of LY-CoV1404 Against Viral Variants of COVID 19

Shots:

  • AbCellera reported that a second Ab from its collaboration with Lilly, LY-CoV1404 has entered clinical trials in patients with mild-to-moderate COVID-19. The program will join Lilly’s ongoing Blaze-4 study where it will be evaluated as monothx. and in combination with other mAbs
  • AbCellera unveils the preclinical data demonstrating LY-CoV1404 binds to a rarely mutated region of the SARS-CoV-2 spike protein and neutralizes all currently known variants of concern
  • In Mar’2020, AbCellera initially mobilized its pandemic response platform and discover the first mAb therapy, bamlanivimab for COVID-19 which FDA has authorized for emergency use

Click here to­ read full press release/ article | Ref: Buisnesswire | Image: AbCellera

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post